Cargando…

Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab(®)

INTRODUCTION: Since epithelial growth factor receptor (EGFR) overexpression is linked to a variety of malignancies, it is an attractive target for immune therapy including chimeric antigen receptor (CAR)-engineered T cells. Unfortunately, CAR T cell therapy harbors the risk of severe, even life-thre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jureczek, Justyna, Feldmann, Anja, Bergmann, Ralf, Arndt, Claudia, Berndt, Nicole, Koristka, Stefanie, Loureiro, Liliana Rodrigues, Mitwasi, Nicola, Hoffmann, Anja, Kegler, Alexandra, Bartsch, Tabea, Bachmann, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297505/ https://www.ncbi.nlm.nih.gov/pubmed/32606767 http://dx.doi.org/10.2147/OTT.S245169

Ejemplares similares

Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells
por: Mitwasi, Nicola, et al.
Publicado: (2017)

UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells
por: Arndt, Claudia, et al.
Publicado: (2020)

An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells
por: Jureczek, Justyna, et al.
Publicado: (2019)

T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression
por: Kegler, Alexandra, et al.
Publicado: (2019)

Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR)
por: Mitwasi, Nicola, et al.
Publicado: (2022)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
por: Mitwasi, Nicola, et al.
Publicado: (2020)

Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers
por: Loureiro, Liliana R., et al.
Publicado: (2020)

Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells
por: Loureiro, L. R., et al.
Publicado: (2018)

From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo
por: Albert, Susann, et al.
Publicado: (2018)

A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR
por: Arndt, Claudia, et al.
Publicado: (2019)

Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells
por: Bachmann, Dominik, et al.
Publicado: (2017)

Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”
por: Feldmann, Anja, et al.
Publicado: (2017)

Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy
por: Kittel-Boselli, Enrico, et al.
Publicado: (2021)

Conventional CARs versus modular CARs
por: Feldmann, Anja, et al.
Publicado: (2019)

Combining Radiation- with Immunotherapy in Prostate Cancer: Influence of Radiation on T Cells
por: Lindner, Diana, et al.
Publicado: (2022)

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML
por: Meyer, Jan-Erik, et al.
Publicado: (2021)

Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy
por: Feldmann, Anja, et al.
Publicado: (2020)

Validation of CD98hc as a Therapeutic Target for a Combination of Radiation and Immunotherapies in Head and Neck Squamous Cell Carcinoma
por: Köseer, Ayşe Sedef, et al.
Publicado: (2022)

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
por: Koristka, Stefanie, et al.
Publicado: (2019)

Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy
por: Arndt, Claudia, et al.
Publicado: (2020)

Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells
por: Saleh, Haidy A., et al.
Publicado: (2023)

A Small Step, a Giant Leap: Somatic Hypermutation of a Single Amino Acid Leads to Anti-La Autoreactivity
por: Bartsch, Tabea, et al.
Publicado: (2021)

T Cell Mediated Conversion of a Non-Anti-La Reactive B Cell to an Autoreactive Anti-La B Cell by Somatic Hypermutation †
por: Bachmann, Michael P., et al.
Publicado: (2021)

Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management
por: Arndt, Claudia, et al.
Publicado: (2022)

Two Be or Not Two Be: The Nuclear Autoantigen La/SS-B Is Able to Form Dimers and Oligomers in a Redox Dependent Manner
por: Berndt, Nicole, et al.
Publicado: (2021)

And Yet It Moves: Oxidation of the Nuclear Autoantigen La/SS-B Is the Driving Force for Nucleo-Cytoplasmic Shuttling
por: Berndt, Nicole, et al.
Publicado: (2021)

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
por: Cartellieri, M, et al.
Publicado: (2016)

Characterization of a Novel Single-Chain Bispecific Antibody for Retargeting of T Cells to Tumor Cells via the TCR Co-Receptor CD8
por: Michalk, Irene, et al.
Publicado: (2014)

A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells
por: Kegler, Alexandra, et al.
Publicado: (2023)

Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy
por: Aliperta, Roberta, et al.
Publicado: (2017)

TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity
por: Cartellieri, Marc, et al.
Publicado: (2013)

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy (†)
por: Sihver, Wiebke, et al.
Publicado: (2014)

Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy
por: Arndt, Claudia, et al.
Publicado: (2023)

Cytotoxic response of human regulatory T cells upon T-cell receptor-mediated activation: a matter of purity
por: Koristka, S, et al.
Publicado: (2014)

A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells
por: Landi, Nicola, et al.
Publicado: (2023)

UniDrug-Target: A Computational Tool to Identify Unique Drug Targets in Pathogenic Bacteria
por: Chanumolu, Sree Krishna, et al.
Publicado: (2012)

EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
por: Reade, Chad A, et al.
Publicado: (2009)

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab
por: Benelli, Roberto, et al.
Publicado: (2022)

A Novel Ex Vivo Isolation and Expansion Procedure for Chimeric Antigen Receptor Engrafted Human T Cells
por: Cartellieri, Marc, et al.
Publicado: (2014)

Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts
por: Aliperta, R, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ttkk2md056ta2kvdpqutn3ksv7